Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2019
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Solid tumours
- Focus Adverse reactions
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.